Learn about PONVORY™ (ponesimod), a prescription medicine that is used to treat relapsing forms of multiple sclerosis
PONVORY™ is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated…
Could BTK Inhibitors Be the Next Big MS Treatment?
by Ed Tobias | July 30, 2021 – The MS Wire Is orelabrutinib one of the next big MS therapies? Biogen…
Stuart Schlossman
Gilenya Started Earlier in RRMS Disease Course in Recent Years
By Marisa Wexler MS on Jul 26, 2021 People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier…
Stuart Schlossman
At-home Tysabri Infusions Appear as Safe, Effective as Those at Clinics
by Forest Ray PhD | July 26, 2021 Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are…
Stuart Schlossman
First-Line Treatment Considerations in RRMS
The NeurologyLive Insights series, “Use of High-Efficacy Therapies for Treatment of Relapsing Multiple Sclerosis,” features Enrique Alvarez, MD, PhD,…
Stuart Schlossman
Relapsing MS Patients May Fare Better on Zeposia Than Aubagio
Treatment with Zeposia (ozanimod) significantly reduces the risk of relapse, decreases the proportion of patients experiencing a relapse, and has a better…
Stuart Schlossman
EC approves Sanofi’s Aubagio for paediatric MS patients
By Lucy Parsons The European Commission has approved Sanofi’s oral multiple sclerosis (MS) therapy Aubagio for the first-line treatment of…
Stuart Schlossman
Janssen’s Multiple Sclerosis Treatment Scores European Approval
The European Commission has approved Janssen’s, a unit of Johnson & Johnson Ponvory (ponesimod), to treat adult patients with relapsing multiple sclerosis.…
Stuart Schlossman
An MS medication in the Pipeline: UBLITUXIMAB (TG-1101) – A Novel Glycoengineered ANTI-CD20 Monoclonal Antibody
Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to…
Stuart Schlossman
Ublituximab Superior to Aubagio at Lowering Relapse Rates, Phase 3 Data Show
Ublituximab, an investigational anti-CD20 antibody, outperformed Aubagio (teriflunomide) in lowering the frequency of relapses among people with active, relapsing forms of multiple…
Stuart Schlossman
